Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Cell Surface Receptor Guides Liver Development

By BiotechDaily International staff writers
Posted on 18 Jun 2013
Identification of a growth factor that directs the differentiation of liver progenitor cells into mature liver cells may pave the way for development of laboratory-grown livers for use in organ transplants that will eliminate the need for living or deceased donors.

Investigators at Mount Sinai School of Medicine (New York, NY, USA) worked with mice and with samples taken from human fetal livers. They discovered that human embryonic stem cells could be differentiated into liver progenitor cells and produce mature liver cells as long at the cells expressed the cell surface growth factor KDR (kinase insert-domain receptor, also known as vascular endothelial growth factor receptor 2).

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. The KDR gene encodes one of the two receptors of VEGF. This receptor, known as kinase insert-domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis, and sprouting. The signaling and trafficking of this receptor are regulated by multiple factors.

The investigators found that the newly differentiated liver cells were fully functional as demonstrated by their ability to be infected by the Hepatitis C virus, a property restricted to liver cells exclusively. KDR-positive progenitor cells were found in both human and mouse liver samples, indicating their importance in the formation of the organ.

"The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy," said senior author Dr. Valerie Gouon-Evans, assistant professor of developmental and regenerative biology at the Mount Sinai School of Medicine. "Until now, liver transplantation has been the most successful treatment for people with liver failure, but we have a drastic shortage of organs. This discovery may help circumvent that problem."

The study was published in the June 6, 2013, online issue of the journal Cell Stem Cell.

Related Links:

Mount Sinai School of Medicine



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.